Samsrita Labs Limited

DRHABEEB

INE579N01018

Healthcare Facilities & Services

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-05-31 EDT			5-day change	1st Jan Change
16.37 ^INR	+2.38%		-3.48%	-5.54%

2023	Samsrita Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI
2023	Samsrita Labs Limited Announces Resignation of Aakauskha as Independent Director	CI

Dr Habeebullah Life Sciences Limited Appoints K.N.V Narendera Kumaras as CFO

February 14, 2020 at 07:53 am

Dr Habeebullah Life Sciences Limited appointed K.N.V Narendera Kumaras as (CFO) of the company at its board meeting held on 14 February, 2020.

Latest news about Samsrita Labs Limited

Samsrita Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
Samsrita Labs Limited Announces Resignation of Aakauskha as Independent Director	23-09-02	CI
Samsrita Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Samsrita Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Samsrita Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-31	CI
Samsritalabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-01	CI
Samsritalabs Limited Reports Earnings Results for the Second Quarter and Half Year Ended September 30, 2022	22-10-28	CI
Samsritalabs Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-10-28	CI
Dr Habeebullah Life Sciences Limited has Changed its Name to SAMSRITALABS LIMITED	22-10-18	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the First quarter Ended June 30, 2021	21-08-11	CI
Dr Habeebullah Life Sciences Limited Announces Change in Registered Office and Corporate Office Address	21-08-11	CI
Dr Habeebullah Life Sciences Limited Announces Management Changes	21-07-02	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-29	CI
Dr Habeebullah Life Sciences Limited Announces Board Changes	21-06-29	CI
Dr Habeebullah Life Sciences Limited Announces Executive Changes	21-02-13	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-13	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-13	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-09-14	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	20-07-29	CI
Dr Habeebullah Life Sciences Limited Suspends its Operations	20-03-26	CI
Dr Habeebullah Life Sciences Limited Appoints K.N.V Narendera Kumaras as CFO	20-02-14	CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-14	CI
Dr Habeebullah Life Sciences Limited Appoints Neha Kankariya as Company Secretary and Compliance Officer	20-01-28	CI

Samsrita Labs Ltd is an India-based biopharma company. The Company is engaged activities, such as trading, exports and imports, manufacturing of bulk drugs, APIs, Specialty drugs, research and development (R&D) through joint ventures or associations or mergers or by its own. It has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease.

Sector

Healthcare Facilities & Services

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SAMSRITA LABS LIMITED	-5.54%	2.9M
SONIC HEALTHCARE LIMITED	-24.16%	7.76B
RADNET, INC.	+68.65%	4.33B
SYNLAB AG	-2.98%	2.64B
DR. LAL PATHLABS LIMITED	+2.72%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-46.17%	2.16B
FLEURY S.A.	-22.12%	1.46B
METROPOLIS HEALTHCARE LIMITED	+13.62%	1.17B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.81%	1.14B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+20.41%	999M